Takashi Shirai
Asahi Kasei
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Takashi Shirai.
Biomaterials | 2003
Akon Higuchi; Kaichiro Sugiyama; Boo Ok Yoon; Masaru Sakurai; Mariko Hara; Masaya Sumita; Shuichi Sugawara; Takashi Shirai
We examined plasma protein adsorption and platelet adhesion to polysulfone (PSf) flat membranes coated with Pluronic with varying polyethylene oxide (PEO) block length. Adsorption of albumin, globulin and fibrinogen to Pluronic-coated PSf membranes was independent of plasma dilution when concentrations of human blood plasma above 20% were applied. Increasing coating concentrations of aqueous Pluronic solution resulted in decreased protein adsorption by the PSf membranes. Pluronic F68, which was more hydrophilic than Pluronic L62 or L64 and had 80% of PEO content, was the most effective at suppressing the adsorption of plasma proteins and platelet adhesion to PSf membranes. We developed a mixed protein solution containing human albumin, gamma-globulin and fibrinogen to attempt to mimic the competitive and cooperative binding effects found in plasma. Fibrinogen adsorption from plasma could be recapitulated by the mixed protein solution. The number of platelets adhering to the PSf membranes decreased as the coating concentration of Pluronic solution was increased, and platelet adhesion decreased in parallel with fibrinogen adsorption. These results suggest that the bioinert property of PEO segments in the Pluronic, which is ascribed to their high flexibility in aqueous media, suppresses the adsorption of plasma proteins and platelets to the Pluronic-coated PSf membranes.
PLOS ONE | 2015
Masaki Kurogochi; Masako Mori; Kenji Osumi; Mami Tojino; Shuichi Sugawara; Shou Takashima; Yuriko Hirose; Wataru Tsukimura; Mamoru Mizuno; Junko Amano; Akio Matsuda; Masahiro Tomita; Atsushi Takayanagi; Shin-ichiro Shoda; Takashi Shirai
Many therapeutic antibodies have been developed, and IgG antibodies have been extensively generated in various cell expression systems. IgG antibodies contain N-glycans at the constant region of the heavy chain (Fc domain), and their N-glycosylation patterns differ during various processes or among cell expression systems. The Fc N-glycan can modulate the effector functions of IgG antibodies, such as antibody-dependent cellular cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC). To control Fc N-glycans, we performed a rearrangement of Fc N-glycans from a heterogeneous N-glycosylation pattern to homogeneous N-glycans using chemoenzymatic approaches with two types of endo-β-N-acetyl glucosaminidases (ENG’ases), one that works as a hydrolase to cleave all heterogeneous N-glycans, another that is used as a glycosynthase to generate homogeneous N-glycans. As starting materials, we used an anti-Her2 antibody produced in transgenic silkworm cocoon, which consists of non-fucosylated pauci-mannose type (Man2-3GlcNAc2), high-mannose type (Man4-9GlcNAc2), and complex type (Man3GlcNAc3-4) N-glycans. As a result of the cleavage of several ENG’ases (endoS, endoM, endoD, endoH, and endoLL), the heterogeneous glycans on antibodies were fully transformed into homogeneous-GlcNAc by a combination of endoS, endoD, and endoLL. Next, the desired N-glycans (M3; Man3GlcNAc1, G0; GlcNAc2Man3GlcNAc1, G2; Gal2GlcNAc2Man3GlcNAc1, A2; NeuAc2Gal2GlcNAc2Man3GlcNAc1) were transferred from the corresponding oxazolines to the GlcNAc residue on the intact anti-Her2 antibody with an ENG’ase mutant (endoS-D233Q), and the glycoengineered anti-Her2 antibody was obtained. The binding assay of anti-Her2 antibody with homogenous N-glycans with FcγRIIIa-V158 showed that the glycoform influenced the affinity for FcγRIIIa-V158. In addition, the ADCC assay for the glycoengineered anti-Her2 antibody (mAb-M3, mAb-G0, mAb-G2, and mAb-A2) was performed using SKBR-3 and BT-474 as target cells, and revealed that the glycoform influenced ADCC activity.
Bioorganic & Medicinal Chemistry | 2017
Kohtaro Goto; Hiroko Ideo; Akiko Tsuchida; Yuriko Hirose; Ikuro Maruyama; Satoshi Noma; Takashi Shirai; Junko Amano; Mamoru Mizuno; Akio Matsuda
Synthesis of several 1,5-Anhydro-d-fructose (1,5-AF) derivatives to evaluate inhibitory activities of the inflammasome was carried out. Recently, 1,5-AF reported to suppress the inflammasome, although with only low activity. We focused on the hydration of 2-keto form of 1,5-AF and speculated that this hydration was the cause of low activity. Therefore, we synthesized some 1,5-AF derivatives that would not be able to form the dimer conformation and can be expected to have high activity against inflammasome, and then evaluated their inhibitory activities with respect to the NLRP3 inflammasome by using mouse bone marrow-derived macrophages and human THP-1 cells. As a result, some synthesized 2-keto form compounds had much higher inhibitory activities with respect to the NLRP3 inflammasome than did 1,5-AF.
Agricultural and biological chemistry | 1989
Takashi Shirai; Noriko Shimizu; Sadayuki Horiguchi; Hirataka Ito
DNA and Cell Biology | 1986
Hirataka Ito; Takashi Shirai; Shuji Yamamoto; Michiaki Akira; Shinji Kawahara; Charles W. Todd; R. Bruce Wallace
Chemical & Pharmaceutical Bulletin | 1978
Minoru Akiyama; Junichi Ohishi; Takashi Shirai; Kageyasu Akashi; Koh-Ichi Yoshida; Johji Nishikido; Hiroshi Hayashi; Yutaka Usubuchi; Daikichi Nishimura; Hirataka Itoh; Chisei Shibuya; Torao Ishida
Journal of Medicinal Chemistry | 1985
Yukiji Shimojima; Takashi Shirai; Tsuneo Baba; Hiroshi Hayashi
DNA and Cell Biology | 1988
Takashi Shirai; Noriko Shimizu; Satoshi Shiojiri; Sadayuki Horiguchi; Hirataka Ito
Archive | 1987
Takashi Shirai; R. Bruce Wallace
Archive | 1999
Takashi Etoh; Kenji Matsuyama; Takashi Shirai